IGFBP3 and non-small cell lung carcinoma: In summary, although IGFBP-3 downregulation is associated with the acquisition of EGFR-TKI resistance regardless of the underlying mechanism, its modest effect on resistance detected in the present study suggests that IGFBP-3 does not play a major role in the resistance of NSCLC cells to EGFR-TKI therapy.